Shares of Veru (VERU) are down $1.25, or 9%, to $12.21 in early trading after short-seller Culper Research released a follow-up short report after having previously issued an initial report on Veru on May 2. The firm, which had previously criticized the company’s Phase III study for sabizabulin in hospitalized COVID-19 patients, said that the company’s July 6 publication in NEJM’s Evidence “revealed more granular data which confirms our view that the Study was plagued by anomalies, which in sum led to a Placebo group which was not in fact ‘similar’ to the treatment group, and instead was much sicker.” The firm continues to believe that “Veru has little to no hope of obtaining an Emergency Use Authorization based on these results as called for by management and ever-obsequious sell-side analysts.”